EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

SLCO1B1 and ABCG2 genotype‐informed phenotypes are related to variation in ramipril exposure

Houwaida Abbes iD, Pablo Zubiaur, Paula Soria-Chacartegui, Tamara de la Torre, Gonzalo Villapalos-García, Carmen Candau, Andrea Rodríguez-Lopez, Eva González-Iglesias, Marina Aldama, Marcos Navares-Gomez, Asma Omezzine, Dolores Ochoa und 1 weitere

Basic & Clinical Pharmacology & Toxicology · 2024

DOI: 10.1111/bcpt.14046 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2024. Verfasst von Houwaida Abbes und 12 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology Department, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria L…. Hauptthemen laut MEDLINE: Angiotensin-Converting Enzyme Inhibitors, ATP Binding Cassette Transporter, Subfamily G, Member 2, Genotype, Liver-Specific Organic Anion Transporter 1. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Tunisian Ministry of Higher Education, Scientific Research and Technology, Universidad Autónoma de Madrid, FPI-UAM-2021 predoctoral fellowship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ramipril is an angiotensin‐converting enzyme inhibitor used for hypertension and heart failure management. To date, scarce literature is available on pharmacogenetic associations affecting ramipril. The goal of this study was to investigate the effect of 120 genetic variants in 34 pharmacogenes (i.e., genes encoding for enzymes like CYPs or UGTs and transporters like ABC or SLC) on ramipril pharmacokinetic variability and adverse drug reaction (ADR) incidence. Twenty‐nine healthy volunteers who had participated in a single‐dose bioequivalence clinical trial of two formulations of ramipril were recruited. A univariate and multivariate analysis searching for associations between genetic variants and ramipril pharmacokinetics was performed. SLCO1B1 and ABCG2 genotype‐informed phenotypes strongly predicted ramipril exposure. Volunteers with the SLCO1B1 decreased function (DF) phenotype presented around 1.7‐fold higher dose/weight‐corrected area under the curve (AUC/DW) than volunteers with the normal function (NF) phenotype (univariate p ‐value [ p uv ] < 0.001, multivariate p ‐value [ p mv ] < 0.001, β = 0.533, R 2 = 0.648). Similarly, volunteers with ABCG2 DF + poor function (PF) phenotypes presented around 1.6‐fold higher AUC/DW than those with the NF phenotype ( p uv = 0.011, p mv < 0.001, β = 0.259, R 2 = 0.648). Our results suggest that SLCO1B1 and ABCG2 are important transporters to ramipril pharmacokinetics, and their genetic variation strongly alters its pharmacokinetics. Further studies are required to confirm these associations and their clinical relevance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiotensin-Converting Enzyme InhibitorsATP Binding Cassette Transporter, Subfamily G, Member 2GenotypeLiver-Specific Organic Anion Transporter 1PhenotypeRamiprilAdultFemaleHumansMaleYoung AdultArea Under CurveHealthy VolunteersNeoplasm ProteinsPharmacogeneticsPharmacogenomic Variants

Stichwörter der Autor:innen

ABCG2SLCO1B1pharmacogeneticspharmacokineticsramipril

Substanzen

ABCG2 protein, humanAngiotensin-Converting Enzyme InhibitorsATP Binding Cassette Transporter, Subfamily G, Member 2Liver-Specific Organic Anion Transporter 1Neoplasm ProteinsRamiprilSLCO1B1 protein, human

Autor:innen und Institutionen

  • Clinical Pharmacology Department, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, Spain.
  • Biochemistry Department, LR12SP11, Sahloul University Hospital, Sousse, Tunisia.
  • Faculty of Pharmacy of Monastir, University of Monastir, Monastir, Tunisia.
  • Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain.

ORCID-Profile: Houwaida Abbes, Francisco Abad-Santos

Förderung

  • Tunisian Ministry of Higher Education, Scientific Research and Technology
  • Universidad Autónoma de Madrid
  • FPI-UAM-2021 predoctoral fellowship
  • Instituto de Salud Carlos III
  • European Social Fund
  • Programa Investigo
  • European Social Fund Plus

Zitieren

APA

Abbes, H., Zubiaur, P., Soria-Chacartegui, P., de la Torre, T., Villapalos-García, G., Candau, C., Rodríguez-Lopez, A., González-Iglesias, E., Aldama, M., Navares-Gomez, M., Omezzine, A., Ochoa, D., & Abad-Santos, F. (2024). SLCO1B1 and ABCG2 genotype‐informed phenotypes are related to variation in ramipril exposure. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.14046

Vancouver

Abbes H, Zubiaur P, Soria-Chacartegui P, de la Torre T, Villapalos-García G, Candau C, et al. SLCO1B1 and ABCG2 genotype‐informed phenotypes are related to variation in ramipril exposure. Basic & Clinical Pharmacology & Toxicology. 2024. doi:10.1111/bcpt.14046

BibTeX
@article{Abbes2024,
  author = {Abbes, Houwaida and Zubiaur, Pablo and Soria-Chacartegui, Paula and de la Torre, Tamara and Villapalos-García, Gonzalo and Candau, Carmen and Rodríguez-Lopez, Andrea and González-Iglesias, Eva and Aldama, Marina and Navares-Gomez, Marcos and Omezzine, Asma and Ochoa, Dolores and Abad-Santos, Francisco},
  title = {SLCO1B1 and ABCG2 genotype‐informed phenotypes are related to variation in ramipril exposure},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2024},
  doi = {10.1111/bcpt.14046}
}
Kostenlos starten →